21 research outputs found
65 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF RHFGF18 ADMINISTERED INTRAARTICULARLY USING SINGLE OR MULTIPLE ASCENDING DOSES IN PATIENTS WFTH PRIMARY KNEE OSTEOARTHRITIS (OA), NOT EXPECTED TO REQUIRE KNEE SURGERY WITHIN 1 YEAR
Get PDFDie orale Einnahme von Kollagen-Hydrolysat verbessert die Gelenkbeweglichkeit bei Patienten mit Gonarthrose
No full textLangzeiteinnahme von Kollagenhydrolysat CH-Alpha® bei Sportlern mit belastungsbedingten Arthralgien
No full text65 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF RHFGF18 ADMINISTERED INTRAARTICULARLY USING SINGLE OR MULTIPLE ASCENDING DOSES IN PATIENTS WFTH PRIMARY KNEE OSTEOARTHRITIS (OA), NOT EXPECTED TO REQUIRE KNEE SURGERY WITHIN 1 YEAR
No full text309 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF rhFGF18 ADMINISTERED INTRAARTICULARLY USING SINGLE OR MULTIPLE ASCENDING DOSES IN PATIENTS WITH PRIMARY KNEE OSTEOARTHRITIS (OA), SCHEDULED FOR TOTAL KNEE REPLACEMENT
No full textRecommended from our members
Corrigendum to "OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hip osteoarthritis" [Osteoarthritis Cartilage, 23, (2015), 761-771, doi: 10.1016/j.joca.2015.03.006]
No full text405 EVALUATION OF THE ABILITY OF DELAYED GADOLINIUM-ENHANCED MRI (DGEMRIC) TO DETECT CHANGE IN CARTILAGE CHARACTERISTICS AMONG INDIVIDUALS WITH KNEE OSTEOARTHRITIS (OA) RECEIVING A COLLAGEN HYDROLYSATE FORMULATION
No full textRecommended from our members
OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hip osteoarthritis.
No full textThe ability to assess the efficacy and effectiveness of an intervention for the treatment of hip osteoarthritis (OA) requires strong clinical trial methodology. This consensus paper provides recommendations based on a narrative literature review and best judgment of the members of the committee for clinical trials of hip OA. We provide recommendations on clinical trial design, outcome measures, including structural (radiography), and patient and physician global assessments, performance based measures, molecular markers and experimental endpoints including MRI imaging. This information can be utilized by sponsors of trials for new therapeutic agents for hip OA
Corrigendum to "OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hip osteoarthritis" [Osteoarthritis Cartilage, 23, (2015), 761-771, doi: 10.1016/j.joca.2015.03.006]
Get PDF
